Phaseline

Targets › CCR7

CCR7 (C-C chemokine receptor type 7): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. (UniProt, P32248)

Open in Phaseline: the race on CCR7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Catapult TherapeuticsCAP-100
humanized antibody against C-C-chemokine receptor 7 (CCR7)
CCR7Phase 1Lymphocytic Leukemia, ChronicJan 2027

Conditions

Lymphocytic Leukemia, Chronic (1)

Modalities

small molecule (1)

Companies

Catapult Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.